RecallRadar
ModerateReported November 26, 2025

Lantiseptic, Dry Skin Therapy, Lanolin USP 30%

Recalled by DermaRite Industries, LLC

Drug recall

DermaRite Industries, LLC

Class II — moderate

Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

DermaRite Industries, LLC has recalled Lantiseptic, Dry Skin Therapy, Lanolin USP 30%, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on November 26, 2025 and was initiated on August 27, 2025. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.

What was recalled?

This recall covers Lantiseptic, Dry Skin Therapy, Lanolin USP 30%, with approximately 8,378 containers affected. The company behind the recall is DermaRite Industries, LLC, based in North Bergen, NJ. The FDA describes the product as: “Lantiseptic, Dry Skin Therapy, Lanolin USP 30%, packaged in a) 5 g (0.17 oz) (NDC 61924-504-05), b) 4 oz (NDC 61924-504-04), and c)14 oz (NDC 61924-710-14) tubes, DermaRite Industries LLC, 7777 West Side Avenue, North Bergen, NJ 07047.”

Why was Lantiseptic, Dry Skin Therapy, Lanolin USP 30% recalled?

According to the FDA, the stated reason for the recall is: “CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.” In plain terms, this recall relates to a manufacturing quality issue (CGMP).

CGMP stands for Current Good Manufacturing Practice — the FDA's quality rules for how medicines must be made, tested, and documented. A CGMP-related recall means the manufacturing process did not meet those standards. It does not automatically mean the medicine is harmful, but the FDA cannot be confident in its quality, so it is removed from the market.

What should you do?

If you think you may have bought Lantiseptic, Dry Skin Therapy, Lanolin USP 30%, compare it against the product description and identifying codes (All lots on or before expiry date 08/2027) before using it. This recall is currently listed as ongoing.

The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact DermaRite Industries, LLC or your local health authority.

About this recall

This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.

Full recall details

Status
Ongoing
Date reported
November 26, 2025
Recall started
August 27, 2025
Distributed in
NJ
What was recalled
Lantiseptic, Dry Skin Therapy, Lanolin USP 30%, packaged in a) 5 g (0.17 oz) (NDC 61924-504-05), b) 4 oz (NDC 61924-504-04), and c)14 oz (NDC 61924-710-14) tubes, DermaRite Industries LLC, 7777 West Side Avenue, North Bergen, NJ 07047.
Why it was recalled (as stated by the FDA)
CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.
How to identify the affected product
All lots on or before expiry date 08/2027
Amount recalled
8,378 containers

What you can do

Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.

Quick answers

Why was Lantiseptic, Dry Skin Therapy, Lanolin USP 30% recalled?+

According to the FDA: CGMP Deviation;

How serious is this recall?+

Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

What should I do if I have Lantiseptic, Dry Skin Therapy, Lanolin USP 30%?+

Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.

Share this recall:PostShareEmail
View the official FDA record

Opens the U.S. Food and Drug Administration (FDA) data for this recall.

Recall number: D-0169-2026. Information last synced from the FDA on July 5, 2026.

Related recalls